Lv L, Liu Y. Clinical application of liquid biopsy in non-Hodgkin lymphoma. Front Oncol. 2021;11: 658234.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sujobert P, Salles G, Bachy E. Molecular classification of diffuse large B-cell lymphoma: what is clinically relevant? Hematol Oncol Clin North Am. 2016;30(6):1163–77.

Article  PubMed  Google Scholar 

Shiels MS, Pfeiffer RM, Besson C, Clarke CA, Morton LM, Nogueira L, et al. Trends in primary central nervous system lymphoma incidence and survival in the U.S. Br J Haematol. 2016;174(3):417–24.

Article  PubMed  PubMed Central  Google Scholar 

Shin SH, Jung KW, Ha J, Lee SH, Won YJ, Yoo H. Population-based incidence and survival for primary central nervous system lymphoma in Korea, 1999–2009. Cancer Res Treat. 2015;47(4):569–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dandachi D, Ostrom QT, Chong I, Serpa JA, Giordano TP, Kruchko C, et al. Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national data. Cancer Causes Control. 2019;30(5):477–88.

Article  PubMed  Google Scholar 

Lv C, Wang J, Zhou M, Xu JY, Chen B, Wan Y. Primary central nervous system lymphoma in the United States, 1975–2017. Ther Adv Hematol. 2022;13:20406207211066170.

Article  PubMed  PubMed Central  Google Scholar 

Roth P, Martus P, Kiewe P, Möhle R, Klasen H, Rauch M, et al. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial. Neurology. 2012;79(9):890–6.

Article  PubMed  Google Scholar 

Ambady P, Fu R, Netto JP, Kersch C, Firkins J, Doolittle ND, et al. Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease. Fluids Barr CNS. 2017;14(1):16.

Article  Google Scholar 

Jahnke K, Thiel E, Martus P, Herrlinger U, Weller M, Fischer L, et al. Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol. 2006;80(2):159–65.

Article  PubMed  Google Scholar 

Dahiya S, Murphy ES, Chao ST, Stevens GH, Peereboom DM, Ahluwalia MS. Recurrent or refractory primary central nervous lymphoma: therapeutic considerations. Expert Rev Anticancer Ther. 2013;13(9):1109–19.

Article  CAS  PubMed  Google Scholar 

Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol. 2006;24(8):1281–8.

Article  CAS  PubMed  Google Scholar 

Hiemcke-Jiwa LS, Minnema MC, Radersma-van Loon JH, Jiwa NM, de Boer M, Leguit RJ, et al. The use of droplet digital PCR in liquid biopsies: a highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid. Hematol Oncol. 2018;36(2):429–35.

Article  CAS  PubMed  Google Scholar 

Shao J, Chen K, Li Q, Ma J, Ma Y, Lin Z, et al. High level of IL-10 in cerebrospinal fluid is specific for diagnosis of primary central nervous system lymphoma. Cancer Manag Res. 2020;12:6261–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu Y, Xiang J, Luo X, Lu M, Xu D, Chen B, et al. Application of cerebrospinal fluid free light chain in diagnosis of primary central nervous system lymphoma and monitoring of associated chemotherapy efficacy. Clin Chim Acta. 2022;533:48–52.

Article  CAS  PubMed  Google Scholar 

Mathieu M, Martin-Jaular L, Lavieu G, Théry C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol. 2019;21(1):9–17.

Article  CAS  PubMed  Google Scholar 

Takashima Y, Kawaguchi A, Iwadate Y, Hondoh H, Fukai J, Kajiwara K, et al. miR-101, miR-548b, miR-554, and miR-1202 are reliable prognosis predictors of the miRNAs associated with cancer immunity in primary central nervous system lymphoma. PLoS ONE. 2020;15(2): e0229577.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iqbal J, Shen Y, Huang X, Liu Y, Wake L, Liu C, et al. Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. Blood. 2015;125(7):1137–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takashima Y, Kawaguchi A, Iwadate Y, Hondoh H, Fukai J, Kajiwara K, et al. MicroRNA signature constituted of miR-30d, miR-93, and miR-181b is a promising prognostic marker in primary central nervous system lymphoma. PLoS ONE. 2019;14(1): e0210400.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beheshti A, Stevenson K, Vanderburg C, Ravi D, McDonald JT, Christie AL, et al. Identification of circulating serum multi-MicroRNA signatures in human DLBCL models. Sci Rep. 2019;9(1):17161.

Article  PubMed  PubMed Central  Google Scholar 

Bouvy C, Wannez A, George F, Graux C, Chatelain C, Dogné JM. Circulating MicroRNAs as biomarkers in diffuse large B-cell lymphoma: a pilot prospective longitudinal clinical study. Biomark Cancer. 2018;10:1179299X18781095.

Article  PubMed  PubMed Central  Google Scholar 

Xiao XB, Gu Y, Sun DL, Ding LY, Yuan XG, Jiang HW, et al. Effect of rituximab combined with chemotherapy on the expression of serum exosome miR-451a in patients with diffuse large b-cell lymphoma. Eur Rev Med Pharmacol Sci. 2019;23(4):1620–5.

PubMed  Google Scholar 

Feng Y, Zhong M, Tang Y, Liu X, Liu Y, Wang L, et al. The role and underlying mechanism of exosomal CA1 in chemotherapy resistance in diffuse large B cell lymphoma. Mol Ther Nucl Acids. 2020;21:452–63.

Article  CAS  Google Scholar 

Swerdlow S, Berger F. WHO classification of tumors of hematopoietic and lymphoid tissues. 2008.

Théry C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006;3:3–22.

Google Scholar 

Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74–87.

Article  PubMed  Google Scholar 

Zhou Q, Xie D, Wang R, Liu L, Yu Y, Tang X, et al. The emerging landscape of exosomal CircRNAs in solid cancers and hematological malignancies. Biomark Res. 2022;10(1):28.

Article  PubMed  PubMed Central  Google Scholar 

Cao D, Cao X, Jiang Y, Xu J, Zheng Y, Kang D, et al. Circulating exosomal microRNAs as diagnostic and prognostic biomarkers in patients with diffuse large B-cell lymphoma. Hematol Oncol. 2022;40(2):172–80.

Article  CAS  PubMed  Google Scholar 

Sundararajan V, Burk UC, Bajdak-Rusinek K. Revisiting the miR-200 family: a clan of five siblings with essential roles in development and disease. Biomolecules. 2022;12(6): 781.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wei J, Liu R, Hu X, Liang T, Zhou Z, Huang Z. MAPK signaling pathway-targeted marine compounds in cancer therapy. J Cancer Res Clin Oncol. 2021;147(1):3–22.

Article  CAS  PubMed  Google Scholar 

Wang M, Zhao Y, Yu ZY, Zhang RD, Li SA, Zhang P, et al. Glioma exosomal microRNA-148a-3p promotes tumor angiogenesis through activating the EGFR/MAPK signaling pathway via inhibiting ERRFI1. Cancer Cell Int. 2020;20:518.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang H, Zhang P, Li J, Gao Y, Zhao L, Li J, et al. Targeting PIN-1 attenuates GCB DLBCL cell proliferation through inhibition of PI3K/AKT signaling. Onco Targ Ther. 2020;13:8593–600.

Article  CAS  Google Scholar 

Blachly JS, Baiocchi RA. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma. Br J Haematol. 2014;167(1):19–32.

Article  CAS  PubMed  Google Scholar 

Senfter D, Holzner S, Kalipciyan M, Staribacher A, Walzl A, Huttary N, et al. Loss of miR-200 family in 5-fluorouracil resistant colon cancer drives lymphendothelial invasiveness in vitro. Hum Mol Genet. 2015;24(13):3689–98.

CAS  PubMed  Google Scholar 

Khare D, Goldschmidt N, Bardugo A, Gur-Wahnon D, Ben-Dov IZ, Avni B. Plasma microRNA profiling: exploring better biomarkers for lymphoma surveillance. PLoS ONE. 2017;12(11): e0187722.

Article  PubMed  PubMed Central  Google Scholar 

Tonon S, Mion F, Dong J, Chang HD, Dalla E, Scapini P, et al. IL-10-producing B cells are characterized by a specific methylation signature. Eur J Immunol. 2019;49(8):1213–25.

Article  CAS  PubMed  Google Scholar 

Rukov JL, Shomron N. MicroRNA pharmacogenomics: post-transcriptional regulation of drug response. Trends Mol Med. 2011;17(8):412–23.

Article  CAS  PubMed  Google Scholar 

El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007;320(1):229–35.

Article  CAS  PubMed  Google Scholar 

Iparraguirre L, Gutierrez-Camino A, Umerez M, Martin-Guerrero I, Astigarraga I, Navajas A, et al. MiR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic